Galle P et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology front wo randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). (Abstract GS-09)
Associatie community-acquired fluorochinolonresistente ‘E. coli’ en gebruik van antibiotica in de omgeving
jun 2019 | Antibioticaresistentie